Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients.

The pandemic caused by the SARS-CoV-2 coronavirus has been especially detrimental to patients with end-stage renal disease. History with other vaccines suggests that patients with renal disease may not respond adequately to the SARS-CoV-2 vaccine. The aim of this study is to evaluate the immunity to SARS-CoV-2 mRNA vaccines in renal patients. Post SARS-CoV-2 vaccination first, and after the booster dose, antibodies and cellular immunity were studied in patients on hemodialysis (N = 20), peritoneal dialysis (N = 10) and renal transplantation (N = 10). After the two doses of vaccine, there was an effective immunity in dialysis patients, with 100% seroconversion and 87% detection of cellular immunity (85% in hemodialysis and 90% in peritoneal dialysis). In contrast, in renal transplant recipients there was only 50% seroconversion and cellular immunity was detected in 30% of patients. After the booster dose, all dialysis patients achieved a cellular and antibody immunity, whereas in transplant patients, despite improvement, 20% did not produce antibodies and in 37.5% cellular immunity could not be detected. The mRNA vaccine plus booster performs excellently in dialysis patients, whereas in kidney transplant recipients, despite the booster, complete immunization is not achieved.

[Atheroembolic renal disease: analysis of clinical and therapeutic factors that influence its progression]. / Enfermedad renal ateroembólica: un análisis de los factores clínicos y terapéuticos que influyen en su evolución.

Cholesterol embolism is a disease caused by distal showering of cholesterol crystal released from disintegration of arterial atheromatous plaques. It may occur spontaneously or more often after invasive vascular procedures or thrombolytic/anticoagulant agents. Forty five cases were diagnosed between 1989 and 2005 in three Spanish hospitals. The diagnosis was confirmed by histology or diagnostic ophthalmoscopic findings. The majority were male (93.3%), elder (55.5% were older than 70 years), smoker (91.1%), had hypertension (95.6%), with high prevalence of cardiovascular risk factors. At the time of diagnosis all patients presented acute renal failure. Mean serum creatinine at diagnosis was 4.3+/- 2.4 mg/dl. The acute renal failure was accompanied with eosinophilia (64.4%) and cutanous lesions (57.7%). 20% of cases occur spontaneously and 46.7% after endovascular manipulation (coronary angiography/arteriography) and only 8% after changes in anticoagulant treatment. After a follow-up of 12 +/- 16.3 months the 55.6% of patients need chronic dialysis, 64.4% died, 8 of them after the beginning of dialysis. Nine patients recovered renal function, with a mean creatinine of 3 +/- 1.7 mg/dl at the end of follow-up. The cardiovascular comorbididy and the clinical severity of the embolism don t have impact in the renal or patient survival. Renal survival (Kaplan-Mier) were better in spontaneous than in iatrogenic cholesterol embolism. Fifteen of 45 patients were treated with steroids. In treated patients we observed a high incidence of death (73.3% versus 60%) and fewer recovery of renal function (13.3% versus 23%), without statistical significance. The mean time to dialysis was shorter in treatment patients (p= 0.017). Statins treatment was not associated with outcome (renal or individual). In summary, atheroembolic renal disease represents an acute renal failure with special characteristics. Renal and individual outcome is poor, but some patients have spontaneous recovery of renal function. Renal survival was significantly better in spontaneous disease. We don t observe beneficial effect of steroid treatment.

[Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis]. / Relación entre comorbilidad, anemia y respuesta a derivados eritropoyéticos en pacientes incluidos en programa de hemodiálisis periódicas.

INTRODUCTION: Patients treated with haemodialysis have a high prevalence of co-morbidity that induces a elevate mortality risk. On the other hand, these patients have anaemia whose treatment is based in erythropoiesis stimulating agents. To date there are not enough studies to determine if co-morbidity alters erythropoietin response and the relationship between co-morbidity, response to treatment of anaemia and resistance to erythropoiesis-stimulating agents. OBJECTIVES: We have the following objectives: i) to study the prevalence of associated diseases in patients treated with haemodialysis in our Hospital Unit and to evaluate the co-morbidity Charlson Index, ii) to know the degree of anaemia control, dose and response to erythropoiesis-stimulating agents, and iii) to determine the relationship with co-morbidity and anaemia treatment. PATIENTS AND METHODS: We designed a retrospective study in stable haemodialysis treated patients. We calculated the Charlson co-morbidity index adjusted to age and we analysed levels of haemoglobin in the 6 months before study, dose of erythropoiesis-stimulating agents and its resistance index defined as doses of erythropoiesis-stimulating agents/weight (kg)/week/haemoglobin (g/dL). The different variables included in Charlson index were considered as independent variables and the index to repose to erythropoiesis-stimulating agents as a dependent variable, using bivariant and multivariate statistical analysis. RESULTS: We included 58 patients (31 males and 27 females), median age of 69.5 years (range 24-88), mean haemodialysis 83.7 months. Mean Charlson index was 7.4 +/- 2.8 (range 2-13). Comorbidity-age Charlson index was 2 in 3.4% of patients; 10.3% had 3 or 4 points; 43.2% between 5 and 7 and 43,1% 8 or more. Mean haemoglobin levels was 11,7+/-1,2 g/dL. Mean erythropoiesis-stimulating agents dose was 163.7+/-114.5 IU/kg/week and resistance index 14.1+/-9.7. Most of patients (57%) had a IRE value higher than 10. Fourteen patients (24%) had haemoglobin less than 11 g/dL, and 3 of them (5.1%) received erythropoiesis-stimulating agents more than 300 IU/kg/week. Nine subjects (15.5%) was treated with high dose of erythropoiesis-stimulating agents (>300 IU/kg/week): 3 of them had Hb>or=11 g/dL and 6 had Hb<11 g/dL. We did not found that the intensity of Charlson index is related with the degree of anaemia control or response to erythropoiesis-stimulating agents. CONCLUSIONS: Although the co-morbidity index is high and the response to erythropoiesis-stimulating agents is inadequate. In our study there is not relationship between these conditions.

[Acute renal failure and hypertension]. / Fracaso renal agudo en paciente hipertenso.

Ischemic nephropathy could be complicated with hypertension and acute worsening of chronic renal failure secondary to ACE inhibitors or AT receptor antagonist treatments and arterial occlusion. We describe a patient with bilateral renal artery stenosis and hypertension treated with ATI receptor antagonist (valsartan) that developed rapid worsening of renal function that required dialysis. Percutaneous transluminal renal artery angioplasty and stenting, complemented with hydratation and valsartan suppression achieves rapid and sustained recovery of renal function.

[Membranous nephropathy and crescentic glomerulonephritis]. / Síndrome nefrótico e insuficiencia renal aguda por nefropatía membranosa y proliferación extracapilar.

The most frequent causes of glomerular diseases whose main clinical syndrome are nephrotic syndrome and acute renal failure may have several causes: acute tubular necrosis, thrombosis of renal veins, acute tubulointerstitial nephritis. Infrequently, the association between primary glomerular disease (membranous nephropathy and others) and crescentic glomerulonephritis can cause this clinical picture. We describe a young woman without systemic disease with nephrotic syndrome and acute renal failure secondary to membranous nephropathy and superimposed crescentic glomerulonephritis. She received steroids and cyclophosphamide with stabilization of renal function after two months of follow-up.

Concordance of estimated glomerular filtration rates using Cockcroft-Gault modification of diet in renal disease, and chronic kidney disease epidemiology in renal transplant recipients.

INTRODUCTION: Various equations have been used to estimate the glomerular filtration rate (GFR) in renal patients, including kidney transplant recipients. Controversy exists concerning which equation is more precise to determine kidney failure. AIM: The aim of this study was to analyze the concordance (bias, variability, and exactness) of GFR estimated by the Modification of Diet in Renal Disease (MDRD4) and the Chronic Kidney Disease Epidemiology (CKD-EPI) equations using the Cockcroft-Gault (CG) method as the reference. MATERIAL AND METHODS: This observational, cross-sectional study included 153 clinically stable patients who underwent kidney transplantation between 2007 and 2009. The GFR was estimated at 12 months after the transplantation using the MDRD and CKP-EPI formula, using CG as the reference. RESULTS: The mean GFR for the various methods was as follows: CG = 65.6 ± 23.3 mL/min/1.73 m(2), MDRD4 = 54.9 ± 19.3 mL/min/1.73 m(2), and CKD-EPI = 55.8 ± 19.6 mL/min/1.73 m(2). Good correlations were found between CG-MDRD4 (r = 0.84; P < .001), CG-CKD-EPI (r = 0.87; P < .001), and MDRD4-CKD-EPI (r = 0.98; P < .001). The analysis of concordance detected a bias (normal difference) of -10.6 ± 12.7 versus -9.8 ± 11.3 mL/min/1.73 m(2) (P = .006), a variability (percent difference) of 14.5 ± 15.4% versus 13.6 ± 14.5% (P = .031), and an exactness (P30) of 81.7% versus 86.9% (P < .001) of CG-MDRD4 versus CG-CKD-EPI, respectively. For a GFR >60 mL/min/1.73 m(2) the exactness was 75.3% versus 83.5% (P < .001) for CG-MDRD4 versus CG-CKD-EPI, and for a GFR ≤ 60 mL/min/1.73 m(2) it was 89.7% versus 91.2% (P < .001). CONCLUSIONS: In our population the CKD-EPI method most approached the CG values, particularly when the GFR was >60 mL/min/1.73 m(2).

Papel de la necrosis tubular aguda por cilindros hemáticos en la glomerulonefritis proliferativa endocapilar / Role of acute tubular necrosis with blood cast during endocapillary proliferative glomerulonephritis

No disponible

Enfermedad renal ateroembólica: un análisis de los factores clínicos y terapéuticos que influyen en su evolución / Atheroembolic renal disease: analysis of clinical and therapeutic factors that influence its progression

El embolismo de colesterol es una enfermedad causada por la suelta de cristales de colesterol desde las placas arterioscleróticas ulceradas de la aorta. Esta suelta puede ocurrir de forma espontánea o más frecuentemente tras procedimientos vasculares invasivos o tras tratamientos anticoagulantes o fibrinolíticos. Entre 1989 y 2005, en tres hospitales españoles, se diagnosticaron 45 casos de embolismo renal de colesterol. El diagnóstico fue confirmado mediante biopsia de cualquier órgano afectado o hallazgos típicos en el fondo de ojo. La mayoría de los pacientes eran varones (93,3%), ancianos (el 55,7% era mayor de 70 años), fumadores (91,1%), hipertensos (95,6%) y con varios factores de riesgo cardiovascular. Todos los pacientes presentaron un fracaso renal agudo en el momento del diagnóstico. La creatinina media al inicio fue de 4,3 ± 2,4 mg/dl. El fracaso renal agudo se acompañó frecuentemente de eosinofilia (64,4%) y lesiones cutáneas (57,7%). El 20% de los casos ocurrieron espontáneamente y el 46,7% tras manipulación endovascular (cateterismo/arteriografía); tan sólo un 8,9% ocurrió tras cambios en la anticoagulación. Tras un seguimiento de 12 ± 16,3 meses, el 55,6% (25) de los pacientes requerían diálisis crónica y un 64,4% (29) había fallecido, ocho de ellos tras haber entrado en diálisis crónica. Se observó una recuperación parcial de función renal en 9 pacientes (20%), que presentaban una creatinina media al final del seguimiento de 3 ± 1,7 mg/dl. La comorbilidad cardiovascular y la gravedad clínica del embolismo de colesterol no tuvieron impacto sobre la supervivencia renal o del individuo. La supervivencia renal (Kaplan-Meier) fue mayor en los casos de ateroembolismo espontáneo que en los iatrogénicos. 15 de los 45 pacientes recibieron esteroides. En los tratados se observó una mayor incidencia de fallecimientos (73,3% frente a 60%) y un menor porcentaje de recuperación de función renal (13,3% frente a 23%), aunque sin diferencias estadísticamente significativas. El tiempo medio de evolución a la diálisis fue significativamente más corto entre los tratados con esteroides (p = 0,017). El uso de estatinas no se asoció con una mejoría en el pronóstico renal o vital del individuo. En conclusión, la enfermedad renal ateroembólica constituye un tipo de fracaso renal agudo con unas características clínicas muy determinadas. La supervivencia renal y del paciente es mala, pero existe un porcentaje significativo de recuperaciones espontáneas de la función renal. La supervivencia renal fue significativamente mejor en los casos espontáneos y no observamos efectos beneficiosos del tratamiento esteroideo (AU)

Cholesterol embolism is a disease caused by distal showering of cholesterol crystal released from disintegration of arterial atheromatous plaques. It may occur spontaneously or more often after invasive vascular procedures or thrombolytic/anticoagulant agents. Forty five cases were diagnosed between 1989 and 2005 in three Spanish hospitals. The diagnosis was confirmed by histology or diagnostic ophthalmoscopic findings. The majority were male (93.3%), elder (55.5% were older than 70 years), smoker (91.1%), had hypertension (95.6%), with high prevalence of cardiovascular risk factors. At the time of diagnosis all patients presented acute renal failure. Mean serum creatinine at diagnosis was 4.3± 2.4mg/dl. The acute renal failure was accompanied with eosinophilia (64.4%) and cutanous lesions (57.7%). 20% of cases occur spontaneously and 46.7% after endovascular manipulation (coronary angiography/arteriography) and only 8% after changes in anticoagulant treatment. After a follow-up of 12 ± 16.3 months the 55.6% of patients need chronic dialysis, 64.4% died, 8 of them after the beginning of dialysis. Nine patients recovered renal function, with a mean creatinine of 3 ± 1.7 mg/dl at the end of follow-up. The cardiovascular comorbididy and the clinical severity of the embolism don´t have impact in the renal or patient survival. Renal survival (Kaplan-Mier) were better in spontaneous than in iatrogenic cholesterol embolism. Fifteen of 45 patients were treated with steroids. In treated patients we observed a high incidence of death (73.3% versus 60%) and fewer recovery of renal function (13.3% versus 23%), without statistical significance. The mean time to dialysis was shorter in treatment patients (p= 0.017). Statins treatment was not associated with outcome (renal or individual). In summary, atheroembolic renal disease represents an acute renal failure with special characteristics. Renal and individual outcome is poor, but some patients have spontaneous recovery of renal function. Renal survival was significantly better in spontaneous disease. We don´t observe beneficial effect of steroid treatment (AU)

Riñón «en herradura», adenocarcinoma renal / No disponible

No disponible

Relación entre comorbilidad, anemia y respuesta a derivados eritropoyéticos en pacientes incluidos en programa de hemodiálisis periódicas / The relationship between comorbidity, anemia and response to erythropoiesis-stimulating agents in chronic hemodialysis

Introducción: Los pacientes en hemodiálisis presentan un elevado número de patologías asociadas. Por otro lado, la mayoría reciben derivados eritropoyéticos como tratamiento de la anemia. No hay estudios que indiquen si el grado de comorbilidad influye en la respuesta a los derivados eritropoyéticos. Objetivos: Estudiar la comorbilidad de los pacientes de una unidad de hemodiálisis hospitalaria, cuantificarla mediante el índice de comorbilidad de Charlson, conocer el control de anemia, la respuesta a derivados eritropoyéticos y, finalmente, evaluar la relación entre comorbilidad y control y tratamiento de la anemia. Pacientes y métodos: Realizamos un estudio retrospectivo. Incluimos 58 pacientes en hemodiálisis del Hospital General de Ciudad Real. Recogimos datos de la historia clínica para calcular el índice de comorbilidad de Charlson. Analizamos las cifras de hemoglobina y las dosis de derivados eritropoyéticos en los seis meses previos y calculamos el índice de resistencia a derivados eritropoyéticos. Las distintas entidades incluidas en el índice de comorbilidad y el propio índice de comorbilidad se consideraron variables independientes y el índice de resistencia a derivados eritropoyéticos como variable dependiente, mediante análisis uni y multivariante. Resultados: Edad media 69,5años; 53,4% varones; tiempo medio en hemdiálisis 83,7meses. El índice de Charlson medio fue 5,2 ± 2,4 (2-11) y el ajustado a la edad 7,4 ± 2,8 (2-13). La hemoglobina media fue 11,7 ± 1,2 g/dL. El 24,1% presentaban hemoglobina inferior a 11 g/dL. La media del índice de resistencia a derivados eritropoyéticos fue 14,1 ± 9,7. No observamos que los valores del índice de Charlson se relacionaran con el grado de anemia ni con la resistencia a derivados eritropoyéticos. Conclusiones: En nuestra muestra existe una elevada comorbilidad asociada y un porcentaje importante de pacientes con anemia no controlada. No hemos encontrado relación entre la comorbilidad y el control de la anemia ni el grado de respuesta a derivados eritropoyéticos (AU)

Introduction: Patients treated with haemodialysis have a highprevalence of co-morbidity that induces a elevate mortality risk. On the other hand, these patients have anaemia whose treatment is based in eritropoyesis stimulating agents. To date there are not enough studies to determine if co-morbidity alters erythropoietin response and the relationship between co-morbidity, response to treatment of anaemia and resistance to erythropoiesis-stimulating agents. Objectives: We have the following Objectives: i) to study the prevalence of associated diseases in patients treated with haemodialysis in our Hospital Unit and to evaluate the co-morbidity Charlson Index; ii) to know the degree of anaemia control, dose and response to erythropoiesis-stimulating agents, and iii) to determine the relationship with comorbidity and anaemia treatment. Patients and methods: We designed a retrospective study in stable haemodialysis treated patients. We calculated the Charlson co-morbidity index adjusted to age and we analysed levels of haemoglobin in the 6months before study, dose of erythropoiesis-stimulating agents and its resistance index defined as doses of erythropoiesis-stimulating agents/weight (kg)/week/haemoglobin (g/dL). The different variables included in Charlson index were considered as independent variables and the index to repose to erythropoiesisstimulating agents as a dependent variable, using bivariant and multivariate statistical analysis. Results: We included 58 patients(31 males and 27 females), median age of 69.5 years (range 24-88), mean haemodialysis 83,7 months. Mean Charlson index was 7.4 ± 2.8 (range 2-13). Comorbidity-age Charlson index was 2 in 3.4% of patients; 10.3% had 3 or 4 points; 43.2% between 5 and 7 and 43.1% 8 or more. Mean haemoglobin levels was 11.7±1.2 g/dL. Mean erythropoiesis-stimulating agents dose was 163.7 ± 114.5 IU/kg/week and resistance index 14.1 ± 9.7. Most of patients (57%) had a IRE value higher than 10. Forteen patients (24%) had haemoglobin less than 11 g/dL, and 3 of them (5.1%) received erythropoiesis-stimulating agents more than 300 IU/kg/week. Nine subjects (15.5%) was treated with high dose of erythropoiesis-stimulating agents (> 300 IU/kg/week): 3 of them had Hb ≥ 11 g/dL and 6 had Hb < 11 g/dL. We did not found that the intensity of Charlson index is related with the degree of anaemia control or response to erythropoiesis-stimulating agents. Conclusions: Althought in our study the comorbidity index is high and the response to erythropoiesis-stimulating agents is inadequate, there is not relationship between these conditions (AU)

Calcifilaxis severa fatal en una paciente trasplantada renal con paratiroidectomía previa / No disponible

No disponible

Fracaso renal agudo en paciente hipertenso / Acute renal failure and hypertension

Los pacientes hipertensos con nefropatía isquémica pueden presentar deterioroagudo de función renal por varias razones, entre ellas tratamiento con IECAs oARAII, deshidratación y oclusión de las arterias renales. Presentamos un caso de hipertensiónarterial secundaria a estenosis bilateral de arterias renales, tratada conARAII (valsartán), que presenta un deterioro agudo de función renal que precisadiálisis. La revascularización mediante angioplastia y colocación de «stent», junto ahidratación y supresión de este fármaco consigue la mejoría y estabilización prolongadade la función renal

Ischemic nephropathy could be complicated with hypertension and acute worseningof chronic renal failure secondary to ACE inhibitors or AT1 receptor antagonisttreatments and arterial occlusion. We describe a patient with bilateral renal arterystenosis and hypertension treated with AT1 receptor antagonist (valsartan) that developedrapid worsening of renal function that required dialysis. Percutaneous transluminalrenal artery angioplasty and stenting, complemented with hydratation andvalsartan suppression achieves rapid and sustained recovery of renal function

Síndrome nefrótico e insuficiencia renal aguda por nefropatía membranosa y proliferación extracapilar / Membranous nephropathy and crescentic glomerulonephritis

Las nefropatías glomerulares que debutan con síndrome nefrótico e insuficienciarenal pueden tener diferentes causas (necrosis tubular, trombosis de venas renales,nefritis intersticial). En raras ocasiones el sustrato morfológico es una nefropatíamembranosa con proliferación extracapilar sobreañadida. Describimos unapaciente, sin nefropatía previa conocida, que debuta con un cuadro de síndromenefrótico e insuficiencia renal aguda sin datos clínicos ni analíticos de enfermedadsistémica, vasculitis por Ac antimembrana basal glomerular. Tras recibir tratamientocon esteroides y ciclofosfamida en forma de «pulsos», la función renal seestabiliza a los dos meses del diagnóstico

The most frequent causes of glomerular diseases whose main clinical syndromeare nephrotic syndrome and acute renal failure may have several causes: acutetubular necrosis, thrombosis of renal veins, acute tubulointerstitial nephritis. Infrequently,the association between primary glomerular disease (membranous nephropathyand others) and crescentic glomerulonephritis can cause this clinical picture.We describe a young woman without systemic disease with nephroticsyndrome and acute renal failure secondary to membranous nephropathy and superimposedcrescentic glomerulonephritis. She received steroids and cyclophosphamidewith stabilization of renal function after two months of follow-up

Calcificación coronaria en paciente en hemodiálisis / No disponible

No disponible